Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 9Terminated 5Not yet recruiting 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 19INDUSTRY 5NIH 4NETWORK 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

CNS 3Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Neoplasms 473Carcinoma, Non-Small-Cell Lung 447Breast Neoplasms 331Neoplasm Metastasis 242Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 191Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 148Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 123Carcinoma, Renal Cell 112Squamous Cell Carcinoma of Head and Neck 110Leukemia, Lymphocytic, Chronic, B-Cell 110Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 87Triple Negative Breast Neoplasms 86Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 74Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

Erlotinib Hydrochloride 2bempegaldesleukin 1Nivolumab 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Ependymoma × Clear all
NCT06038760 2025-07-30

PEAR-GLIO

Ourotech, Inc.

Terminated
12 enrolled
CNS

Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Neoplasms, Oligodendroglioma

NCT01032070 2024-12-12

PETEY

Astellas Pharma Inc

Phase 2 Terminated
25 enrolled 23 charts

Familial ependymoma, Ependymoma, Recurrence

NCT01247922 2024-12-06

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Astellas Pharma Inc

Phase 2 Terminated
4 enrolled 9 charts

Familial ependymoma, Ependymoma

NCT04730349 2023-03-24

PIVOT IO 020

Bristol-Myers Squibb

Phase 1/2 Terminated
15 enrolled 14 charts
CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell

NCT03967093 2021-07-22

KOURAGE

Bexion Pharmaceuticals, Inc.

Phase 1 Terminated
9 enrolled
CNS

Brain Neoplasms, Ependymoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡